Seminars in Nuclear Medicine
Volume 38, Issue 2 , Pages S13-S18, March 2008

Natural History of Hepatocellular Carcinoma and Current Treatment Options

  • Jean-Luc Raoul, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Jean-Luc Raoul, MD, PhD, Centre Régional de Lutte Contre le Cancer, E. Marquis, 35042 Cedex Rennes, France.

Centre Régional de Lutte Contre le Cancer, Cedex Rennes, France.

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and the most severe complication of chronic liver disease. The annual number of new cases worldwide is approximately 550,000, representing more than 5% of human cancers and is the third leading cause of cancer-related deaths. The stages of the malignancy as well as the severity of the underlying liver disease are essential factors in planning the therapeutic approach. Curative treatment options are represented mainly by surgery (ie, resection or transplantation), but most patients are not candidates for a curative option, and only palliative treatment could be given to these patients. Among palliative treatments, only chemoembolization has been proven to be effective, but other options are currently being investigated. Major risk factors for HCC are well known and are dependent on the geographic area. In Europe, the United States, and Japan, the main risk factors are liver cirrhosis, hepatitis B and C virus, alcohol, and tobacco; in contrast, in Africa and Asia, these factors are hepatitis B and C virus, tobacco use, and aflatoxin exposure. Cirrhosis from any cause is a predisposing factor for HCC and could be considered as a premalignant condition. The present concept of carcinogenesis in HCC is a multistage process. This article describes the natural history of HCC and discusses the various treatment options available at present.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflict of Interest: None.

PII: S0001-2998(07)00120-1

doi:10.1053/j.semnuclmed.2007.10.004

Seminars in Nuclear Medicine
Volume 38, Issue 2 , Pages S13-S18, March 2008